초록 ▼

An antiparkinsonian agent comprising DL- or L-threo-3,4-dihydroxyphenylserine and a decarboxylase inhibitor (e.g. carbidopa and benserazide), which is useful for the treatment of parkinson\s disease, particularly treatment of the freezing phenomenon which has not previously been cured by the convent

An antiparkinsonian agent comprising DL- or L-threo-3,4-dihydroxyphenylserine and a decarboxylase inhibitor (e.g. carbidopa and benserazide), which is useful for the treatment of parkinson\s disease, particularly treatment of the freezing phenomenon which has not previously been cured by the conventional antiparkinsonian drugs such as L-DOPA.

대표청구항 ▼

A method for treating parkinson\s disease in a patient for whom treatment with L-DOPA and a decarboxylase inhibitor is substantially ineffective, which comprises administering a pharmaceutically effective amount of DL- or L-threo-3,4-dihydrophenylserine or a pharmaceutically acceptable acid addition

A method for treating parkinson\s disease in a patient for whom treatment with L-DOPA and a decarboxylase inhibitor is substantially ineffective, which comprises administering a pharmaceutically effective amount of DL- or L-threo-3,4-dihydrophenylserine or a pharmaceutically acceptable acid addition salt thereof and a decarboxylase inhibitor selected from the group consisting of carbidopa, benserazide, the hydrochloride of benserazide and methyldopa to a patient suffering from parkinson\s disease, said decarboxylase inhibitor being used in an amount of 0.025 to 0.5 mole to 1 mole of the DL- or L-threo-3,4-dihydroxyphenylserine. A method according to claim 5, wherein DL- or L-threo-3,4-dihydroxyphenylserine or said salt thereof is orally administered in an amount of from 0.1 to 4 g per day.